Advanced Accelerator Applications

New York,  NY 
United States
  • Booth: 542

Advanced Accelerator Applications, a Novartis company, is an innovative radiopharmaceutical company developing, producing and commercializing molecular nuclear medicine theragnostics. AAA’s theragnostic platform is based on radiolabeling a targeting molecule with either gallium Ga 68 for diagnostic use, or lutetium Lu 177 for therapy. AAA’s first theragnostic pairing for neuroendocrine tumors includes diagnostic drugs NETSPOT® and SomaKit TOC®; and therapeutic Lutathera®. Additional theragnostics in development target gastrointestinal stromal tumors (GIST), and prostate and breast cancer.

Brands: NETSPOT® after radiolabeling with Ga 68 is a radioactive diagnostic agent indicated for use with positron emission tomography for localization of SST positive NETs in adult and pediatric patients.

For Technical Support with this webpage, please contact support.